Member Info for Bobbler

Https://www.oncologypipeline.com/apexonco/blood-cancer-gene-therapies-enter-clinic

Chk1 x2 mentioned here entering trials, might be worth digging into the background

Again Potnak I agree with you. Im no scientist, maybe those in the know (potential buyers) will be able to make a very good judgment from the data, coupled with the effects similar compounds have and come to a positive conclusion on the likelihood it will work. I assume that must be possible otherwise how can JR make claims of “significant advantages over competitors molecules”?

Of course he could be talking out of his balloon knot! Who knows 😬

Potnak, personally yes, for 2 reasons. One I’m sick of the wife reminding me how much I could have walked away with before tax free. And secondly because I’ve built a pretty good holding during the dips, so it would be enough for me. The longer you wait the less time you have to enjoy it. More time behind me than in front 😀

Krone, I hear what you are saying ref £3.

But I do think there is a significant percentage of shares held by people who would take it and walk away with big sums.

I agree with Potnak statement “ I can't see any phama stumping up the cash when they can license for a fraction of the valuation. ”

However, this may only be applicable if there’s only one interested party. Hypothetically, if you have two serious bidders then there is a significant rise in the probability that one will offer a b/o so as to secure the IP. Realistically a ten fold offer now circa £300m is nothing for a large pharma but would very likely be voted through by the share holders.

Analogous art in patent law refers to prior art references that are considered relevant to your invention's obviousness analysis. And in order to be considered analogous, it must be one of two things, one, within the same field or endeavor as your invention or two, reasonably pertinent to the particular problem with which the invention is involved.

My guess is this means 1802 is protected by the patent, hence the reference to Cancer. Patent law is however incredibly complicated.

And cancers……. Clearly linking 1801 success with 1802 potential

We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers."

The data must be impressive for him to make such a bold statement.

“data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors. ”

To me that’s a clear indicator all is very good 👍

Carter- I had 3 heart attacks inside a couple of days, this happened not long after my first covid jab.

I also followed the Oliver Reed school of thought and was sponsored by Benson and Hedges for nearly 30 years. My cardiologist didn’t think the jab played a big part in a complete blockage of the left anterior descending (LAD) artery, aka as the Window Maker.

Interesting read with regards to the rules of when an offer has to be announced.

https://code.thetakeoverpanel.org.uk/tp/rules/rule-2/rule-2-2.html

Aber: it’s means for every 1 share purchased it will return 3 thousand per cent, and if 6 million people believe this and buy in we will all be happy.

Let me know if you need any other codes deciphering 👍

It’s been very tight ship to date. Previous news, such as HNWI buying has never seen preemptive buying.

Bailiff, that’s unfair. I know for a fact that funny guy has been responsible for running at least one bath.

HBD, thats scuppered that theory then! 😡

Thanks for delving, like you say, the search goes on 👍

Interesting read……

https://www.boehringer-ingelheim.com/careers/are-combination-therapies-answer-battling-kras-cancers

“But a new combination therapy we have in trial is working to deactivate the protein, effectively turning it off like a light switch. Dr Ulrich Dünzinger, who is leading the project, calls it a “game-changer” for patients with KRAS cancers.”

I still feel Boehringer Ingelheim are a strong possibility for the “unnamed US private owned company”.

Abstract from a previous study:

“ Lastly, we show that combined checkpoint inhibition induces apoptotic cell death in KRAS- or BRAF-mutant tumor cells directly isolated from patients. These results strongly recommend simultaneous Chk1- and MK2 inhibition as a therapeutic strategy for the treatment of KRAS- or BRAF-driven cancers”

Boehringer Ingelheim Appear to be active in the development of MK2 inhibition.

Just a thought.

Not always 7am 😊

Deucravacitinib, sold under the brand name Sotyktu, It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.

Here’s the bit that makes you realise why this could be so valuable.

The average retail price for Sotyktu is $8,348.71 per 30, 6MG Tablet.

$278 per tablet.

Hi Aber, nowt as strange as folk!

ADVfN board is a strange set up, couple of posters just talking to each other, obsessed with the demise of Sareum.

I can imagine a pair of fat knackers with Chippy Teets , shovelling Macdonalds down them why they fester in their own body fluids.